REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called IC19/1563 for people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recogn…
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can shrink tumors in people with diffuse large B-cell lymphoma that has relapsed or become resistant. The study will enroll 36 adults and measure how many patients respond and…
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The ther…
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy takes on tough lymphoma
Disease control Recruiting nowThis study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. The goal is to see if this combo can …
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental combo targets Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs—zanubrutinib and odronextamab—is safe for people with Richter's transformation, a rare and aggressive form of blood cancer that arises from chronic lymphocytic leukemia. The study will enroll 23 adults and monitor for …
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC